CLAIMS:

1. A compound of Formula (Ia) or (Ib):


(Ia); or

(Ib);

or a pharmaceutically acceptable salt thereof;

wherein:

Z is O or S;

Y represents:

 ,

 ,

 ,

 , or

 ;

X is N or CR^2;

L is -(C_1-C_6)alkylenyl-;

B represents (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl, 4-7 membered heterocycloalkyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more instances of (C_1-C_6)alkyl;

R^1 is hydrogen, -CO_2R^a -$CONR^aR^b$, -SO_2R^a, -$SONR^aR^b$, -$SO_2NR^aR^b$, -NR^aR^b, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy,  , or –O-(4- to 7-membered heterocycloalkyl); wherein (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl and –O-(4- to 7-membered heterocycloalkyl) are each optionally substituted with one or more substituents independently selected from halo, hydroxy, oxo, cyano, amino, phenyl, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, carboxamido, sulfonamido, aminoalkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, hydroxy(C_3-C_8)cycloalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl,  , (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, and benzyl; or when Y represents –L-B-, R^1 taken together with the atom to which it is attached forms a 4- to 7-membered heterocycloalkyl ring, provided that if Y is  or  , then R^1 is not hydrogen;

R^{1a}, R^{1b}, and R^{1c} are independently for each occurrence hydrogen, (C_1-C_6)alkyl, or (C_3-C_8)cycloalkyl; or R^{1a} and R^{1b} taken together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl;

R^2 is hydrogen, fluoro, chloro, cyano, hydroxyl, NH_2, $NHCO(C_1$-$C_6)$alkyl, NHR^a, (C_1-C_6)alkoxy, -$CONR^aR^b$ or (C_1-C_6)alkyl, wherein (C_1-C_6)alkyl is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, and NR^aR^b; or R^1 and R^2 taken together with the atom to which they are attached form a 4- to 9-membered heterocycloalkyl optionally substituted with one or more substituents independently selected from (C_1-C_6)alkyl, wherein the (C_1-C_6)alkyl is further optionally substituted with (C_3-C_8)cycloalkyl, 4- to 7-membered heterocylcylalkyl, hydroxy, halo, (C_1-C_6)alkoxy, cyano, carboxy, -$CONR^aR^b$, and -SO_2R^a;

R^3 is (C_1-C_6)alkyl or (C_3-C_8)cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from halo, hydroxy, (C_1-C_6)alkoxy, (C_3-C_8)cycloalkyl, aryl, carboxamido, amino, cyano, carboxy, and alkoxycarbonyl;

R^a and R^b are independently for each occurrence hydrogen, (C_1-C_6)alkyl, or 4- to 7-membered heterocycloalkyl, wherein (C_1-C_6)alkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; or R^a and R^b taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

R^{5a}, R^{5b}, R^{6a}, and R^{6b} are independently hydrogen or (C_1-C_6)alkyl;

R^A is hydrogen or (C_1-C_6)alkyl;

n, m, and p are independently 0 or 1; and

q is 0, 1, or 2;

provided that the sum of p and q equals 0, 1, or 2.

2. A compound of Formula (Ia) or (Ib):



(Ia); or



(Ib);

or a pharmaceutically acceptable salt thereof;

wherein:

Y represents:



,


,


,


, or


;

X is N or CR^2;

L is -(C_1-C_6)alkylenyl-;

B represents (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl, 4-7 membered heterocycloalkyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more instances of (C_1-C_6)alkyl;

R^1 is hydrogen, -CO_2R^a -$CONR^aR^b$, -SO_2R^a, -$SONR^aR^b$, -$SO_2NR^aR^b$, -NR^aR^b, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, 
, or –O-(4- to 7-membered heterocycloalkyl); wherein (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl and –O-(4- to 7-membered heterocycloalkyl) are each optionally substituted with one or more substituents independently selected from halo, hydroxy, oxo, cyano, amino, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, carboxamido, sulfonamido, aminoalkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, hydroxy(C_3-C_8)cycloalkyl, (C_1-C_6)haloalkyl, (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, 
, (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, and benzyl; or when Y represents –L-B-, R^1 taken together with

the atom to which it is attached forms a 4- to 7-membered heterocycloalkyl ring, provided that if Y is  or  , then R^1 is not hydrogen;

R^{1a}, R^{1b}, and R^{1c} are independently for each occurrence hydrogen, $(C_1\text{-}C_6)$alkyl, or $(C_3\text{-}C_8)$cycloalkyl; or R^{1a} and R^{1b} taken together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl;

R^2 is hydrogen, fluoro, chloro, cyano, hydroxyl, NH_2, $NHCO(C_1\text{-}C_6)$alkyl, NHR^a, $(C_1\text{-}C_6)$alkoxy, $-CONR^aR^b$ or $(C_1\text{-}C_6)$alkyl, wherein $(C_1\text{-}C_6)$alkyl is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, $(C_1\text{-}C_6)$alkoxy, and NR^aR^b; or R^1 and R^2 taken together with the atom to which they are attached form a 4- to 9-membered heterocycloalkyl optionally substituted with one or more substituents independently selected from $(C_1\text{-}C_6)$alkyl, wherein the $(C_1\text{-}C_6)$alkyl is further optionally substituted with $(C_3\text{-}C_8)$cycloalkyl, 4- to 7-membered heterocylcylalkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, cyano, carboxy, $-CONR^aR^b$, and $-SO_2R^a$;

R^3 is $(C_1\text{-}C_6)$alkyl or $(C_3\text{-}C_8)$cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from halo, hydroxy, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_8)$cycloalkyl, aryl, carboxamido, amino, cyano, carboxy, and alkoxycarbonyl;

R^a and R^b are independently for each occurrence hydrogen, $(C_1\text{-}C_6)$alkyl, or 4- to 7-membered heterocycloalkyl, wherein $(C_1\text{-}C_6)$alkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, $(C_1\text{-}C_6)$alkoxy, 4- to 7-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; or R^a and R^b taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

R^{5a}, R^{5b}, R^{6a}, and R^{6b} are independently hydrogen or $(C_1\text{-}C_6)$alkyl;

n, m, and p are independently 0 or 1; and

q is 0, 1, or 2;

provided that the sum of p and q equals 0, 1, or 2.

3. A compound of Formula (Ia) or (Ib):


(Ia); or  (Ib);

or a pharmaceutically acceptable salt thereof;

wherein:

Y represents:

 ,

 ,

 ,

 , or

 ;

X is N or CR^2;

L is -(C_1-C_6)alkylenyl-;

B represents (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl, 4-7 membered heterocycloalkyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more instances of (C_1-C_6)alkyl;

R^1 is hydrogen, -CO_2R^a -$CONR^aR^b$, -SO_2R^a, -$SONR^aR^b$, -$SO_2NR^aR^b$, -NR^aR^b, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-


C_6)alkoxy, or ; wherein (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, and 4- to 7-membered heterocycloalkyl are each optionally substituted with one or more substituents independently selected from halo, hydroxy, oxo, cyano, amino, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, carboxamido, sulfonamido, aminoalkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)haloalkyl, and (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, and


; or when Y represents –L-B-, R^1 taken together with the atom to which it is attached forms a 4- to 7-membered heterocycloalkyl ring, provided that if Y is  or


, then R^1 is not hydrogen;

R^{1a}, R^{1b}, and R^{1c} are independently for each occurrence hydrogen or (C_1-C_6)alkyl; or R^{1a} and R^{1b} taken together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl;

R^2 is hydrogen, fluoro, chloro, cyano, hydroxyl, NH_2, NHCO(C_1-C_6)alkyl, NHR^a, (C_1-C_6)alkoxy, -$CONR^aR^b$ or (C_1-C_6)alkyl optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, and NR^aR^b; or R^1 and R^2 taken together with the atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

R^3 is (C_1-C_6)alkyl or (C_3-C_8)cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from halo, hydroxy, (C_1-C_6)alkoxy, (C_3-C_8)cycloalkyl, carboxamido, amino, cyano, carboxy, and alkoxycarbonyl;

R^a and R^b are independently for each occurrence hydrogen, (C_1-C_6)alkyl, or 4- to 7-membered heterocycloalkyl, wherein (C_1-C_6)alkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; or

R^a and R^b taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

n, m, and p are independently 0 or 1; and

q is 0, 1, or 2;

provided that the sum of p and q equals 0, 1, or 2.

4. The compound of any one of claims 1 to 3, wherein R^1 is:

hydrogen,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , , ,  , , , , , , , , , , , , , or ;

wherein:

R^{1d}, R^{1e}, and R^{1f} are independently for each occurrence selected from hydrogen, (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, (C_1-C_6)hydroxyalkyl and (C_1-C_6)alkoxy, wherein (C_1-C_6)alkyl is further optionally substituted with (C_3-C_8)cycloalkyl or phenyl; or R^{1d} and R^{1e} taken together

with the carbon to which they are attached form a (C_3-C_8)cycloalkyl or a 3- to 7-membered heterocycloalkyl each of which is optionally substituted with hydroxy.

5. The compound of any one of claims 1 to 3, wherein R^1 is:



6. The compound of any one of claims 1 to 4, wherein Y is



7. The compound of any one of claims 1 to 5, wherein X is CR^2; and R^2 is hydrogen.

8. The compound of any one of claims 1 to 5, wherein X is CR^2; and R^2 is methyl.

9. The compound of any one of claims 1 to 5, wherein X is CR^2; and R^1 and R^2 taken together with the atom to which they are attached form a 4- to 9-membered heterocycloalkyl, wherein the 4- to 9-membered heterocycloalkyl is optionally substituted with one or more independently selected instances of $(C_1\text{-}C_6)$alkyl, wherein the $(C_1\text{-}C_6)$alkyl is further optionally substituted with one or more substitutents independently selected from $(C_3\text{-}C_8)$cycloalkyl, phenyl, 4- to 7-membered heterocyloalkyl, hydroxy, halo, $(C_1\text{-}C_6)$alkoxy, cyano, carboxy, $-CONR^aR^b$, and $-SO_2R^a$.

10. The compound of claim 9, wherein R^1 and R^2 taken together with the atom to which they are attached form:


, 
, 
, or 
;

wherein R^{1g} and R^{1h} are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, wherein the $(C_1\text{-}C_6)$alkyl is optionally substituted with one or more substitutents independently selected from $(C_3\text{-}C_8)$cycloalkyl, 4- to 7-membered heterocylcylalkyl, hydroxy, halo, $(C_1\text{-}C_6)$alkoxy, cyano, carboxy, $-CONR^aR^b$, and $-SO_2R^a$.

11. The compound of claim 9, wherein R^1 and R^2 taken together with the atom to which they are attached form:


, 
, 
, 
, 
, 
, 
, 
, 
, 
, or 
.

12. The compound of any one of claims 1, 2, and 4, wherein B represents:

 ,  ,  ,  ,  ,  ,

 ,  ,  ,  ,  , or  .

13. The compound of any one of claims 1 to 5 and 12, wherein L represents methylene, ethylene, or n-butylene.

14. The compound of any one of claims 1 to 13, wherein R^{5a}, R^{5b}, R^{6a}, and R^{6b} are each hydrogen.

15. The compound of any one of claims 1 and 4 to 14, wherein Z is O.

16. The compound of any one of claims 1 to 15, wherein R^3 is methyl, n-propyl, n-butyl,

 ,  ,  ,  , or  .

17. The compound of any one of claims 1 to 3, having the structure:

 ,  ,

 ,  ,


,


,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,


,

,

,

,


,

,

,

,


,

,

,


,

,

,

,


,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

, ,

,

,

,

,

,

,

,

,


,

,

,

,

;

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,


,

,


,

,


,

,


,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

, or ;

or a pharmaceutically acceptable salt thereof.

18. The compound of any one of claims 1 to 3, having the structure:


,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

, or

,

or a pharmaceutically acceptable salt thereof.

19. The compound of any one of claims 1 to 3, having the structure:


,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

override: S
,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.

20. The compound of any one of claims 1 to 3, having the structure:


,

,

,

,

,

,

,

,



,



,


override: R

,



,



,



,


override: R

,



,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

override: R
,

,

override: R
,

,

,

,

,


,

,

override: R
,

,

,

,

,

,


,

,

or a pharmaceutically acceptable salt thereof.

21. A compound according to Formula (IIa) or (IIb):


(IIa); or

(IIb);

or a pharmaceutically acceptable salt thereof;

wherein:

Y represents:


,


,


,


,or


;

X is N or CR^2;

L is -(C_1-C_6)alkylenyl-;

B represents (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more instances of (C_1-C_6)alkyl;

R^1 is hydrogen, -CO_2R^a -$CONR^aR^b$, -SO_2R^a, -$SONR^aR^b$, -$SO_2NR^aR^b$, -NR^aR, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, or  ; wherein (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, and 4- to 7-membered heterocycloalkyl are each optionally substituted with one or more substituents independently selected from halo, hydroxy, oxo, cyano, amino, 4- to 7-membered heterocycloalkyl 5- to 6-membered heteroaryl, carboxamido, sulfonamido, aminoalkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)haloalkyl, and (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, and  ; or when Y represents –L-B-, R^1 taken together with the atom to which it is attached forms a 4- to 7-membered heterocycloalkyl ring, provided that if Y is  ,  , or (C_1-C_6)alkylene, then R^1 is not hydrogen;

R^{1a}, R^{1b}, and R^{1c} are independently for each occurrence hydrogen or (C_1-C_6)alkyl; or R^{1a} and R^{1b} taken together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl;

R^2 is hydrogen, fluoro, chloro, -$CONR^aR^b$ or (C_1-C_6)alkyl optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, and (C_1-C_6)alkoxy; or R^1 and R^2 taken together with the atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

R^3 is (C_1-C_6)alkyl or (C_3-C_8)cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from halo, hydroxy, (C_1-C_6)alkoxy, (C_3-C_8)cycloalkyl, carboxamido, amino, cyano, carboxy, and alkoxycarbonyl;

R^a and R^b are independently for each occurrence hydrogen,(C_1-C_6)alkyl, or 4- to 7-membered heterocycloalkyl, wherein (C_1-C_6)alkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; or R^a and R^b taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

n, m, and p are independently 0 or 1;

q is 0, 1, or 2;

provided that the sum of p and q equals 0, 1, or 2;

Z is S or O;

R^4 is H, -$C(O)NH_2$, (C_1-C_6)alkyl, -$NHSO_2Me$, or -$N(R^{4a})_2$; and

R^{4a} is independently for each occurrence hydrogen or (C_1-C_6)alkyl.

22. The compound of claim 21, wherein R^1 is:

hydrogen,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .


; and

R^{1d}, R^{1e}, and R^{1f} are independently for each occurrence selected from hydrogen, (C_1-C_6)alkyl, (C_1-C_6)haloalkyl, and (C_1-C_6)alkoxy; or R^{1d} and R^{1e} taken together with the carbon to which they are attached form a (C_3-C_8)cycloalkyl or a 3- to 7-membered heterocycloalkyl.

23. The compound of claim 21 or 22, wherein Y is


or .

24. The compound of claim 21 or 22, wherein X is CR^2; and R^2 is hydrogen.

25. The compound of claim 21 or 22, wherein X is CR^2; and R^2 is methyl.

26. The compound of claim 21 or 22, wherein X is CR^2; and R^1 and R^2 taken together with the atom to which they are attached form a 4- to 7-membered heterocycloalkyl.

27. The compound of claim 26, wherein R^1 and R^2 taken together with the atom to which they are attached form:

 ,  ,  , or  .

28. The compound of any one of claims 21 to 27, wherein R^3 is: methyl,  ,  ,  ,  ,  ,  ,  , or  .

29. The compound of any one of claims 21 to 28, wherein Z is O.

30. The compound of any one of claims 21 to 29, wherein R^4 is H.

31. The compound of any one of claims 21 to 29, wherein R^4 is NH_2.

32. The compound of claim 21, having the structure:

 ,  ,

 ,  ,


,

,

,

,

,

,

,

,

;

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

, or

;

or a pharmaceutically acceptable salt thereof.

33. The compound of claim 21, having the structure:


,

,

,

,

,

,

,

,


,

,


,

;

, or

,

or a pharmaceutically acceptable salt thereof.

34. The compound of claim 21, having the structure:



,


, 
,

, 
,

, 
,

, 
,

, or 
;

or a pharmaceutically acceptable salt thereof.

35. A compound according to Formula (IIIa), (IIIb), (IIIc), or (IIId):


(IIIa); 
(IIIb);

 (IIIc); or  (IIId);

or a pharmaceutically acceptable salt thereof;

wherein:

Y-R^1 represents:

 ,

 ,

 ,

 ,

 , or

-(C_1-C_6)alkylene-R^1;

X is N or CR^2;

L is -(C_1-C_6)alkylenyl-;

B represents (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more instances of (C_1-C_6)alkyl;

R^1 is hydrogen, -CO_2R^a -$CONR^aR^b$, -SO_2R^a, -$SONR^aR^b$, -$SO_2NR^aR^b$, -NR^aR, 4- to 7-membered heterocycloalkyl, 5- to 6-membered heteroaryl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-



C_6)alkoxy, or ; wherein (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)alkoxy, and 4- to 7-membered heterocycloalkyl are each optionally substituted with one or more substituents independently selected from halo, hydroxy, oxo, cyano, amino, 4- to 7-membered heterocycloalkyl 5- to 6-membered heteroaryl, carboxamido, sulfonamido, aminoalkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)haloalkyl, and (C_1-C_6)alkoxy, (C_1-C_6)hydroxyalkyl, and



; or when Y represents –L-B-, R^1 taken together with the atom to which it is attached forms a 4- to 7-membered heterocycloalkyl ring, provided that if Y is  ,



, or (C_1-C_6)alkylene, then R^1 is not hydrogen;

R^{1a}, R^{1b}, and R^{1c} are independently for each occurrence hydrogen or (C_1-C_6)alkyl; or R^{1a} and R^{1b} taken together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl;

R^2 is hydrogen, fluoro, chloro, -$CONR^aR^b$ or (C_1-C_6)alkyl optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, and (C_1-C_6)alkoxy; or R^1 and R^2 taken together with the atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

R^3 is (C_1-C_6)alkyl or (C_3-C_8)cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from halo, hydroxy, (C_1-C_6)alkoxy, (C_3-C_8)cycloalkyl, carboxamido, amino, cyano, carboxy, and alkoxycarbonyl;

R^a and R^b are independently for each occurrence hydrogen,(C_1-C_6)alkyl, or 4- to 7-membered heterocycloalkyl, wherein (C_1-C_6)alkyl and 4- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, (C_1-C_6)alkoxy, 4- to 7-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; or R^a and R^b taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl;

n, m, and p are independently 0 or 1;

q is 0, 1, or 2;

provided that the sum of p and q equals 0, 1, or 2;

R^4 is H or $N(R^{4a})_2$; and

R^{4a} is independently for each occurrence hydrogen or $(C_1\text{-}C_6)$alkyl.

36. The compound of claim 35, wherein R^1 is:

hydrogen,  ,  , 



, or

38. The compound of any one of claims 35 to 37, wherein R^3 is: methyl,  ,



, or .

39. The compound of any one of claims 35 to 36, wherein R^4 is H.

40. The compound of any one of claims 35 to 36, wherein R^4 is NH_2.

41. The compound of claim 35, having the structure:



, or

;

or a pharmaceutically acceptable salt thereof.

42. Use of the compound of any one of claims 1-41, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

43. The compound of any one of claims 1-41, or a pharmaceutically acceptable salt thereof, for use in therapy.